Patrick Mayr1, Georg Aumann2, Tina Schaller1, Gerhard Schenkirsch3, Matthias Anthuber2, Bruno Märkl4. 1. Institute of Pathology, Zentralklinikum Augsburg, Stenglinstrasse 2, 86156, Augsburg, Germany. 2. Department of Visceral and Transplantation Surgery, Klinikum Augsburg, Augsburg, Germany. 3. Clinical and Population-Based Cancer Registry of Augsburg, Klinikum Augsburg, Augsburg, Germany. 4. Institute of Pathology, Zentralklinikum Augsburg, Stenglinstrasse 2, 86156, Augsburg, Germany. bruno.maerkl@klinikum-augsburg.de.
Abstract
PURPOSE: Lymph node size as a prognostic parameter has not been investigated well in the past. Recent data, however, have indicated that this parameter could be even more important than the lymph node count. METHODS: Based on the results of earlier studies, we analyzed the lymph node size and number of node-negative colon cancer patients with regard to survival. Data from 115 node-negative cases of colon cancer were analyzed. Lymph nodes with diameters ≤5 mm were defined as small, and all other lymph nodes were classified as intermediate/large in size and labeled LN5. All of the cases were categorized according to the number of LN5s. The LN5 very low (LN5vl) group included cases with less than two LN5s. All of the other cases were assigned to the LN5 low/high (LN5l/h) group. RESULTS: The overall survival analysis revealed significantly worse outcomes for the LN5vl group, with a mean survival of 34 months compared to the LN5l/h group, with a mean survival of 40 months (P = 0.022). After adjusting for the pT1/2 and pT3/4 stages, we still found a significant outcome difference (P = 0.012). Multivariate analysis identified LN5vl and T-stage as being independently correlated with the outcome. The vast majority of LN5vl cases (91 %) were located in the left colon. The location itself, however, was not prognostic (P = 0.478). CONCLUSION: LN5 count, as a marker of immune response, could be shown as being prognostic in node-negative colon cancer. Patients with low LN5 counts showed poor outcomes. These patients could perhaps profit from adjuvant chemotherapy.
PURPOSE: Lymph node size as a prognostic parameter has not been investigated well in the past. Recent data, however, have indicated that this parameter could be even more important than the lymph node count. METHODS: Based on the results of earlier studies, we analyzed the lymph node size and number of node-negative colon cancerpatients with regard to survival. Data from 115 node-negative cases of colon cancer were analyzed. Lymph nodes with diameters ≤5 mm were defined as small, and all other lymph nodes were classified as intermediate/large in size and labeled LN5. All of the cases were categorized according to the number of LN5s. The LN5 very low (LN5vl) group included cases with less than two LN5s. All of the other cases were assigned to the LN5 low/high (LN5l/h) group. RESULTS: The overall survival analysis revealed significantly worse outcomes for the LN5vl group, with a mean survival of 34 months compared to the LN5l/h group, with a mean survival of 40 months (P = 0.022). After adjusting for the pT1/2 and pT3/4 stages, we still found a significant outcome difference (P = 0.012). Multivariate analysis identified LN5vl and T-stage as being independently correlated with the outcome. The vast majority of LN5vl cases (91 %) were located in the left colon. The location itself, however, was not prognostic (P = 0.478). CONCLUSION: LN5 count, as a marker of immune response, could be shown as being prognostic in node-negative colon cancer. Patients with low LN5 counts showed poor outcomes. These patients could perhaps profit from adjuvant chemotherapy.
Authors: Wouter Willaert; Marc Mareel; Dirk Van De Putte; Yves Van Nieuwenhove; Piet Pattyn; Wim Ceelen Journal: Cancer Treat Rev Date: 2013-09-25 Impact factor: 12.111
Authors: Bruno Märkl; Tina Schaller; Ines Krammer; Claudio Cacchi; Hans M Arnholdt; Gerhard Schenkirsch; Hallie Kretsinger; Matthias Anthuber; Hanno Spatz Journal: Mod Pathol Date: 2013-04-19 Impact factor: 7.842
Authors: D A M Sloothaak; S Grewal; H Doornewaard; P van Duijvendijk; P J Tanis; W A Bemelman; E S van der Zaag; C J Buskens Journal: Br J Surg Date: 2014-03-26 Impact factor: 6.939
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Campbell S D Roxburgh; Donald C McMillan; Colin H Richards; Manal Atwan; John H Anderson; Tim Harvey; Paul G Horgan; Alan K Foulis Journal: Ann Surg Date: 2014-06 Impact factor: 12.969
Authors: Bruno Märkl; Therese G Kerwel; Hendrik G Jähnig; Daniel Oruzio; Hans M Arnholdt; Claus Schöler; Matthias Anthuber; Hanno Spatz Journal: Am J Clin Pathol Date: 2008-12 Impact factor: 2.493
Authors: Philipp Schrembs; Benedikt Martin; Matthias Anthuber; Gerhard Schenkirsch; Bruno Märkl Journal: PLoS One Date: 2018-08-10 Impact factor: 3.240